New drug under Real-World watch for duchenne patients

NCT ID NCT07127978

Recruiting now Disease control Sponsor: ITF Therapeutics LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study follows about 300 people with Duchenne muscular dystrophy who are taking the drug givinostat as part of their normal care. Researchers will track safety issues like low platelet counts and bleeding, and see how patients' muscle function changes over up to 5 years. The goal is to understand how well the drug works outside of a controlled trial setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy muscular dystrophy Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENE MUSCULAR DYSTROPHY

Contacts and locations

Locations

Ann and Robert H. Lurie Children's Hospital of Chicago
RECRUITING

Chicago, Illinois, 60611, United States
Arkansas Children's Research Institute
RECRUITING

Little Rock, Arkansas, 72202, United States
Boston Children's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Children's National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Duke University / Lenox Baker Children's Hospital
RECRUITING

Durham, North Carolina, 27705, United States
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239, United States
Seattle Children's Hospital
RECRUITING

Seattle, Washington, 98105, United States
University of Massachusetts Chan Medical School
RECRUITING

Worcester, Massachusetts, 01655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.